Enhanced in vitro antitumor activity of gnRH-III-daunorubicin bioconjugates influenced by sequence modification by Schuster, S. et al.
pharmaceutics
Article
Enhanced In Vitro Antitumor Activity of
GnRH-III-Daunorubicin Bioconjugates
Influenced by Sequence Modification
Sabine Schuster 1,2, Beáta Biri-Kovács 1,2, Bálint Szeder 3 , László Buday 3, János Gardi 4 ,
Zsuzsanna Szabó 5, Gábor Halmos 5 and Gábor Mezo˝ 1,2,*
1 Faculty of Science, Institute of Chemistry, Eötvös Loránd University, 1117 Budapest, Hungary;
sabine.schuster83@gmail.com (S.S.); biri.beata@gmail.com (B.B.-K.)
2 MTA-ELTE Research Group of Peptide Chemistry, Hungarian Academy of Sciences,
Eötvös Loránd University, 1117 Budapest, Hungary
3 Research Centre for Natural Sciences, Institute of Enzymology, Hungarian Academy of Sciences,
1117 Budapest, Hungary; szederbalint@gmail.com (B.S.); buday.laszlo@ttk.mta.hu (L.B.)
4 First Department of Internal Medicine, Faculty of Medicine, University of Szeged, 6720 Szeged, Hungary;
gardi.janos@med.u-szeged.hu
5 Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary;
szabo.zsuzsanna@pharm.unideb.hu (Z.S.); halmos.gabor@pharm.unideb.hu (G.H.)
* Correspondence: gmezo@elte.hu; Tel.: +36-1-372-2500
Received: 20 September 2018; Accepted: 6 November 2018; Published: 9 November 2018 
Abstract: Receptors for gonadotropin releasing hormone (GnRH) are highly expressed in various
human cancers including breast, ovarian, endometrial, prostate and colorectal cancer. Ligands like
human GnRH-I or the sea lamprey analogue GnRH-III represent a promising approach for the
development of efficient drug delivery systems for targeted tumor therapy. Here, we report on the
synthesis and cytostatic effect of 14 oxime bond-linked daunorubicin GnRH-III conjugates containing
a variety of unnatural amino acids within the peptide sequence. All compounds demonstrated
a reduced cell viability in vitro on estrogen receptor α (ERα) positive and ERα negative cancer
cells. The best candidate revealed an increased cancer cell growth inhibitory effect compared to our
lead-compound GnRH-III-[4Lys(Bu),8Lys(Dau=Aoa)]. Flow cytometry and fluorescence microscopy
studies showed that the cellular uptake of the novel conjugate is substantially improved leading to an
accelerated delivery of the drug to its site of action. However, the release of the active drug-metabolite
by lysosomal enzymes was not negatively affected by amino acid substitution, while the compound
provided a high stability in human blood plasma. Receptor binding studies were carried out to
ensure a high binding affinity of the new compound for the GnRH-receptor. It was demonstrated
that GnRH-III-[2∆His,3D-Tic,4Lys(Bu),8Lys(Dau=Aoa)] is a highly potent and promising anticancer
drug delivery system for targeted tumor therapy.
Keywords: targeted cancer therapy; drug delivery system; daunorubicin; gonadotropin releasing
hormone III; peptide drug conjugates; oxime linkage; antitumor activity; cellular uptake
1. Introduction
Targeted cancer therapy is a promising tool to overcome the drawbacks of classical chemotherapy
like the lack of selectivity, toxicity to healthy tissue and the development of multidrug resistance
forced by high dose treatments. In general, ligands with high binding affinities to tumor-specific
receptors or receptors which are overexpressed on the surface of cancer cells can be used as carriers
for anticancer drugs enabling the selective delivery of an effective cytotoxic agent or radionuclides
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to tumor cells. Peptide ligands provide valuable properties such as excellent tissue permeability,
low immunogenicity and structural simplicity. In comparison to protein-based biopharmaceuticals
like monoclonal antibodies, an additional benefit is that peptides can be produced cost-efficiently
in large scale by chemical synthesis [1,2]. Especially, the good progress in peptide technology,
solid phase synthesis and chemical ligation techniques facilitates the synthesis and modification
of peptides [3,4]. The main problem of the application of peptide therapeutics is their relatively short
plasma half-life and the corresponding in vivo stability. The proteolytic digestion of the peptides can
be prevented or reduced by incorporating unnatural amino acids (e.g., D-amino acids) or peptide
cyclization [5–7]. Replacing one or more amino acids with their D-version may not only enhance the
proteolytic stability but also lead to an improved or reduced activity and/or receptor affinity of the
compounds. Prominent examples hereby are gonadotropin-releasing hormone (GnRH) agonists and
antagonists like triptorelin and cetrorelix, which have been developed by Schally and coworkers [8,9].
Both peptide-based pharmaceutics were approved by the Food and Drug Administration (FDA) at
the beginning of this century [10,11]. Cetrorelix acetate was the first GnRH antagonist on the market
and is used to prevent premature luteinizing hormone (LH) surges in women undergoing controlled
ovarian stimulation, whereas triptorelin pamoate received approval for the palliative treatment of
advanced prostate cancer [10–12]. These potent GnRH analogs bind like the natural peptide hormone
GnRH-I (<EHWSYGLRPG-NH2; <E is pyroglutamic acid) to pituitary GnRH receptor (GnRH-R) on
gonadotrophs [13,14]. The native ligand of this seven-transmembrane G-protein coupled receptor
regulates and stimulates the synthesis and release of gonadotropins like LH and follicle stimulating
hormone (FSH), whereby the application of GnRH analogs causes inhibition of gonadotropin release,
which can occur by two different mechanisms of action [12]. Thus, a constant exposure to GnRH
agonists triggers a desensitization of the gonadotropic cells as well as the downregulation of the
receptor level on the cell surface followed by a reduced LH and FSH release [15]. In contrast,
the administration of GnRH antagonist leads to a direct but reversible competitive receptor blockage
causing an immediate inhibition of the gonadotropin release [15,16]. In addition, it has been discovered
that GnRH-Rs are not only expressed in pituitary but also on the surface of various human tumor cells
including breast cancer, prostate cancer, and endometrial cancer [17]. Based on these findings, efficient
cytotoxic GnRH-I derivatives were developed in Schally’s laboratory [18–22]. The most prominent
conjugate AEZS-108 (ZoptrexTM, previously AN-152) consists of a GnRH-I-[6D-Lys] targeting moiety
and the antitumor agent doxorubicin (Dox), which was conjugated to the side chain of the 6D-Lys
through an ester bond by insertion of a glutaryl spacer. It has been demonstrated that AEZS-108
internalizes selectively in GnRH-R expressing cells followed by an intracellular release of the drug
by tumor-specific carboxylesterases [20]. Thus, the antitumor effect of AEZS-108 was intensively
studied in vitro and in vivo revealing a significant tumor growth inhibition and regression of several
tumor types in vivo [17,23–25]. Due to the positive results, preclinical studies and clinical trials were
performed up to phase III. Unfortunately, AEZS-108 could not achieve its primary endpoint in clinical
phase III studies on endometrial cancer, which was caused by the lack of a significant difference in the
median period of overall survival of patients treated with Zoptrex™ as compared to patients treated
with doxorubicin [26]. The main reason for this might be the poor enzymatic stability of the conjugate
in circulation. It has been shown that the ester bond can be hydrolyzed rapidly by carboxylesterases in
presence of mouse (t1/2 = 19 min) and human serum (t1/2 = 126 min) [27]. Taking this into account,
drug-linkers with higher enzymatic stability under physiological conditions might help to overcome
this weakness and ensure antitumor activity without toxic side effects. A variety of linkage systems
like ester, hydrazone, oxime or amide bond have been developed to link anthracyclines like Dox
or daunorubicin (Dau) to GnRH-based targeting moieties [28–30]. Hereby, the oxime linked drug
conjugates revealed the highest chemical and enzymatical stability [30].
Similarly to GnRH-I derivatives, GnRH-III (<EHWSHDWKPG–NH2) based peptide carriers
have been also used in our laboratories to deliver anticancer agents like Dau selectively to GnRH-R
expressing cancer cells [28–31]. This native GnRH-I analog, isolated from sea lamprey, binds to
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GnRH-R on cancer cells and displays a direct antiproliferative activity on several cancer cell lines,
whereby the LH and FSH releasing potency is extremely reduced [32]. Therefore, GnRH-III and its
derivatives are considered selective and efficacious targeting moieties and represent an excellent
starting point for the design of potential homing devices for targeted tumor therapy. In the past
decade, a variety of GnRH-III-Dau conjugates containing an oxime bond have been developed in our
laboratories, whereby Dau was attached to an incorporated aminooxyacetyl moiety (Aoa) and 8Lys
was mainly used as the conjugation site. To improve the antitumor activity and other biochemical
properties of the compounds, many different strategies have been followed including the insertion
of cathepsin B labile peptide linkers or oligoethylene glycol-based spacer as well as the replacement
of 4Ser by an acylated lysine or dimeric GnRH-III conjugates [29,33–36]. One of our most potent and
efficient bioconjugates is GnRH-III-[4Lys(Bu), 8Lys(Dau=Aoa)] (K2), in which the Ser in position four
was replaced by a butyrylated lysine [34]. Recent studies demonstrated that our lead compound K2
possesses an enhanced stability in the presence of gastrointestinal enzymes in comparison to the 4Ser
containing counterpart (K1) as well as an increased in vitro and in vivo antitumor activity [34,37].
The aim of the present work was to achieve an improved inhibitory effect on the growth of cancer
cells by incorporating various unnatural amino acids into the GnRH-III sequence. Based on previously
reported antiproliferative activity studies of drug-free GnRH-III derivatives [38], we synthesized and
characterized a series of novel GnRH-III-Dau conjugates. Hereby, Cordopatis and coworkers have
been reported that a variety of amino acid substitutions lead to an increased antiproliferative activity
of GnRH-III derivatives on GnRH-R positive prostate cancer cell lines [38].
Here we report on the synthesis of 14 novel GnRH-III-[8Lys(Dau=Aoa)] conjugates with modified
peptide sequences. Next to the influence of amino acid substitutions in position 3 and 7 by D-amino
acids, the effect of changing the C-terminal region and the presence of a negative charge in position
six was studied. For a better comparison and to ensure that no cross interactions are caused,
all selected changes were performed for two different groups of compounds, one group with the
natural serine in position four and a second group where the serine was exchanged by butyrylated
lysine. All synthesized conjugates were analyzed for their growth inhibitory effect on GnRH-R
expressing MCF-7 human breast cancer and HT-29 human colon cancer cells. The best candidate
was chosen for a detailed biochemical evaluation including stability in human plasma, lysosomal
degradation in the presence of rat liver lysosomal homogenate, cellular uptake by flow cytometry and
confocal laser scanning microscopy (CLSM) as well as receptor binding affinity.
2. Materials and Methods
2.1. Chemical Reagents
Amino acid derivatives, K-Oxyma Pure® and Rink-Amide MBHA resin were obtained from Iris
Biotech GmBH (Marktredwitz, Germany), Novabiochem®/Merck-Millipore (Darmstadt, Germany)
and Bachem (Bubendorf, Switzerland). Boc-aminooxyacetic acid (Boc-Aoa–OH), aminooxyacetic acid,
scavengers, coupling agents (1-hydroxybenzotriazole hydrate (HOBt), N,N′-diisopropylcarbodiimide
(DIC)), and cleavage reagents (triisopropylsilane (TIS), piperidine, 1,8-diazabicyclo(5.4.0)undec-7-ene
(DBU), trifluoroacetic acid (TFA), diisopropylethylamine (DIPEA), acetic anhydride (Ac2O), methanol
(MeOH), n-butyric anhydride and solvent for HPLC acetonitrile (ACN) were purchased from
Sigma-Aldrich Kft (Budapest, Hungary). Daunorubicin hydrochloride was provided from IVAX
(Budapest, Hungary). N,N-Dimethylformamide (DMF), dichloromethane (DCM) and diethyl ether
(Et2O) were purchased from Molar Chemicals Kft (Budapest, Hungary). All reagents and solvents
were of analytical grade or highest available purity.
2.2. Synthesis of Oxime Linked GnRH-III-[8Lys(Dau=Aoa)] Bioconjugates
The 14 Dau-GnRH-III conjugates were prepared manually by solid phase peptide synthesis
(SPPS) according to Fmoc/tBu chemistry on a Rink-Amide MBHA resin (0.73 mmol/g coupling
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capacity) or on a Fmoc-Ethyl-Indole AM resin (0.94 mmol/g coupling capacity). Afterwards, Dau was
conjugated to the peptides in solution via oxime bond formation. For the peptide synthesis, the listed
Fmoc-protected amino acid derivatives were used: Fmoc-Gly–OH, Fmoc-Pro–OH, Fmoc-Lys(Mtt)-OH,
Fmoc-Lys(Dde)–OH, Fmoc-Trp-OH, Fmoc-D-Trp–OH, Fmoc-Asp(OtBu)–OH, Fmoc-Asp(OMe)–OH,
Fmoc-His(Trt)–OH, Fmoc-Ser(tBu)–OH, Fmoc-D-Tic–OH. Pyroglutamic acid (Glp or <E) was coupled
to the N-terminus of the peptides without any protection. The derivatives were synthesized by
the following protocol, initially, the resin was washed with DMF (4 × 1 min), followed by Fmoc
deprotection with 2% piperidine, 2% DBU in DMF (4 times; 2 + 2 + 5 + 10 min). For the coupling
reaction 3 eq of α-Fmoc-protected amino acid derivative, 3 eq DIC and 3 eq HOBt in DMF were used
(60 min). To ensure that the coupling was successful, the resin was washed with DMF (3 × 1 min)
and DCM (2 × 1 min), and a ninhydrin test was performed. After peptide chain elongation, the Dde
group of 4Lys was cleaved with 2% hydrazine in DMF (12 × 5 min) and the resin-bound peptide was
washed with DMF (5 × 1 min). In the next step, the butyrylation of the ε-NH2 amino group was
performed with 3 eq butyric anhydride and 3 eq DIPEA in DMF (2 h). Afterwards, the Mtt group of
8Lys was removed by using 2% TFA in DCM (6 × 5 min). The peptidyl resin was neutralized with
10% DIPEA in DCM (3 × 5 min) and Boc-Aoa-OH was coupled with DIC and HOBt (3 eq each) for
2 h. The deprotection of the side chain protecting groups and simultaneous cleavage of the peptide
from the resin, was carried out with 95% TFA, 2.5% TIS and 2.5% water (v/v/v) in the presence of
10 eq free aminooxyacetic acid as “carbonyl capture” reagent (2 h, at room temperature (RT)) [39].
Peptides were precipitated with ice-cold Et2O, centrifuged, washed 3 times, dissolved in water-ACN
(0.1% TFA) 4:1 (v/v) and lyophilized. After purification of the crude peptides by RP-HPLC, the eluent
was evaporated and Dau was ligated to the aminooxyacetylated 8Lys. To perform the oxime bond
formation, 10 mg/mL peptide and 1.3 eq Dau were dissolved in 0.2 M NH4OAc buffer (pH 5.0) and
stirred overnight at RT [28]. After purification by RP-HPLC, the resulting GnRH-III bioconjugates
were freeze-dried and characterized by analytical RP-HPLC and ESI-MS.
2.3. RP-HPLC
For the purification of the crude peptides and the bioconjugates, a KNAUER 2501 HPLC system
(H. Knauer, Bad Homburg, Germany) was used either with a preparative Phenomenex Luna® C18(2)
column (100 Å, 10 µm, 250 mm× 21.2 mm) or with a semipreparative Phenomenex Jupiter® C4 column
(300 Å, 10 µm, 250 mm × 10 mm) (Torrance, CA, USA). Linear gradient elution (0 min 20% B; 5 min
20% B; 50 min 80% B) with eluent A (0.1% TFA in water) and eluent B (0.1% TFA in ACN/H2O (80:20,
v/v)) used at a flow rate of 15 mL/min for preparative and 4 mL for semipreparative HPLC. Peaks
were detected at 220 or 280 nm.
A KNAUER 2501 HPLC system was used to prove the purity of the compounds. As a stationary
phase, either a Phenomenex Luna C18 column (100 Å, 5 µm, 250 mm × 4.6 mm) or a Vydac 214TP5 C4
column (300 Å, 5 µm, 250 mm × 4.6 mm) was used. A linear gradient elution (0 min 0% B; 5 min 0%
B; 40 min 90%) was used at a flow rate of 1 mL/min with the eluents described above. Peaks were
detected at 220 nm.
2.4. Mass Spectrometry
Electrospray ionization (ESI) mass spectrometric analyses were performed on an Esquire 3000+
ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany). Spectra were acquired in the
50–2500 m/z range. Samples were dissolved in a mixture of ACN/water (1:1, v/v) and 0.1% formic acid.
For liquid chromatography-mass spectrometry (LC-MS) the same ESI mass spectrometer was
used with an Agilent 1100 HPLC system and a diode array detector (Agilent, Waldbronn, Germany).
A Supelco C18 column (150 mm × 2.1 mm, 3 µm) (Hesperia, CA, USA) was used with a linear gradient
from 2–70% B in 25 min (eluent A: ddH2O, 0.1% HCOOH; eluent B: 80% ACN, 0.1% HCOOH at a
flow rate of 0.2 mL/min) to separate the peptides. Spectra were recorded in positive ion mode in the
100–2500 m/z range.
Pharmaceutics 2018, 10, 223 5 of 19
2.5. Degradation of GnRH-III Bioconjugates in Rat Liver Lysosomal Homogenate
The rat liver lysosomal homogenate was prepared as previously described [29]. A Qubit Protein
Assay Kit (ThermoFisher Scientific, Waltham, MA, USA) was used according to the manufacturer’s
protocol to determine the protein concentration. The bioconjugates were dissolved in ddH2O to a
concentration of 5 µg/µL. For the lysosomal digestion, an identical concentration of bioconjugate
and rat liver lysosomal homogenate (0.25 µg/µL) was incubated in 0.2 M NH4OAc buffer (pH 5) at
37 ◦C. Aliquots of 15 µL were taken at 5 min, 1, 2, 4, 8 and 24 h and quenched with 2 µL of acetic acid.
The analysis of the samples was performed by LC-MS.
2.6. Stability in Human Plasma
GnRH-III-(Dau) conjugates were dissolved in ddH2O and diluted with human plasma (90%) to a
final concentration of 10 µM. The mixture was incubated at 37 ◦C and aliquots were taken after 0.5, 1, 2,
4, 8 and 24 h. The reaction was quenched by adding 10 µL of acetic acid. Large human plasma proteins
were removed using ultra centrifugal filters with a cut-off of 10 kDa (Merck Millipore, Darmstadt,
Germany). The lower molecular weight fraction was analyzed by LC-MS. Two control measurements
have been performed in the same manner (1. 90% plasma plus 10% ddH2O; 2. 10 µM of bioconjugate
in 100% ddH2O).
2.7. Cell Culturing
Dulbecco’s Modified Eagle Medium (DMEM, Lonza, Basel, Switzerland), supplemented with
10% (v/v) Fetal Bovine Serum (FBS, Lonza), L-glutamine (2 mM, Lonza), non-essential amino acids
(NEAA, Sigma-Aldrich Kft), sodium pyruvate (1 mM, Lonza) and Penicillin-Streptomycin (Lonza)
was used to culture MCF-7 human breast adenocarcinoma cells (ATCC:HTB-22). HT-29 human colon
adenocarcinoma cells (ATCC:HTB-38) were maintained in RPMI-1640 (Lonza), supplied with 10% FBS,
L-glutamine and Penicillin-Streptomycin. MDA-MB-231 breast adenocarcinoma cells were cultured in
DMEM (Lonza), supplemented with 10% FBS and Penicillin-Streptomycin. Cells were maintained in
plastic culture dishes at 37 ◦C with a humidified atmosphere containing 5% CO2/95% air.
2.8. In Vitro Cytostatic Effect
5 × 103 cells per well were seeded to 96-well plates (Sarstedt, Nümbrecht, Germany), in a
complete cell medium. After 24 h, the cells were treated with bioconjugates in a serum-free medium
(concentration range 0.068–150 µM, control wells were treated with a serum-free medium). On the next
day, cells were washed two times with a serum-free medium and incubated in a complete medium
for 48 h. The cell viability was determined using alamarBlue reagent® (ThermoFisher Scientific) by
following the manufacturer’s instructions. A Synergy H4 multi-mode microplate reader (BioTek,
Winooski, VT, USA) was used for fluorescence detection (λEx = 570 and at λEM = 620 nm). Experiments
were performed twice, using four parallels per concentration. Cell viabilities (and IC50 values) were
calculated with Origin Pro8 (OriginLab Corp., Northampton, MA, USA.) using a nonlinear regression
(sigmoidal dose–response).
2.9. Cellular Uptake Determination by Flow Cytometry
The cellular uptake of the bioconjugates was studied on MCF-7 and HT-29 cells. Cells were seeded
(105 cells/well) in a complete cell medium to 24-well plates (Sarstedt). On the next day, the cells were
treated with the conjugates (3.125 to 50 µM) in a serum-free medium After 6 h, cells were washed
with HPMI medium (100 mM NaCl, 5.4 mM KCl, 0.4 mM MgCl2, 0.04 mM CaCl2, 10 mM Hepes,
20 mM glucose, 24 mM NaHCO3 and 5 mM Na2HPO4 at pH 7.4) and detached with trypsin-EDTA
(10 min, 37 ◦C). Trypsinization was stopped by HPMI/10% FBS and cells were centrifuged at 216× g
for 5 min at 4 ◦C. Afterwards, the supernatant was removed and the cells were resuspended in HPMI
medium. To detect the intracellular fluorescence intensity (that is proportional to the cellular uptake),
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samples were measured by a BD LSR II flow cytometer (BD Bioscience, Franklin Lakes, NJ, USA) and
the obtained data were analyzed by FACSDiVa (BD Bioscience) 5.0 software.
2.10. Confocal Microscopy Imaging
MCF-7 cells were seeded in a complete cell medium to 24-well plates, which contained cover
glasses (thickness 1, Assistant, Karl Hecht GmbH & Co KG, Sondheim/Rhön, Germany). After one
day, the treatment was performed in a serum-free medium for different time points (5, 15, 30 and 60 s as
well as 5, 10, 30 and 60 min). Afterwards, cells were washed twice with phosphate buffered saline (PBS)
and fixed by 4% paraformaldehyde for 20 min at 37 ◦C. To stain the nuclei, the samples were washed
three times with PBS and incubated for 15 min with 4′,6-diamidine-2-phenylindole dihydrochloride
(DAPI, 0.2 µg/mL, dissolved in PBS, Sigma-Aldrich Kft). After washing, cover glasses were mounted
to microscopy slides (VWR International, Debrecen, Hungary) by Mowiol® 4–88 mounting medium
(Sigma-Aldrich Kft). Confocal microscopy studies were performed on a Zeiss LSM 710 system (Carl
Zeiss Microscopy GmbH, Jena, Germany) with a 40X oil objective and ZEN Lite (Carl Zeiss Microscopy
GmbH) software was used for image processing.
2.11. Western Blotting
GnRH-receptor expression was determined by western blot analysis of whole cell lysates. Cells
(106 cells/well) were seeded one day in advance to six-well plates (Sarstedt) in duplicates. Before
harvesting, the cells were washed two times with PBS and lysed in lysis buffer (50 mM Tris pH 7.4,
150 mM NaCl, 2 mM EDTA, 1% Triton-X 100 and Protease Inhibitor Cocktail (Halt)). Samples were
incubated for 30 min on ice followed by 30 min centrifugation at 16,000× g. Total protein quantity of the
supernatant was measured with the Qubit Protein Assay Kit (Thermo Fisher Scientific). Subsequently,
cell lysates containing an equal amount of total protein were loaded to 10% Tris-tricine gel and then
blotted to a PVDF membrane (Merck Millipore). To detect the GnRHR receptor, an anti-GnRH-R
antibody was used (Proteintech, Rosemant, IL, USA, Catalog Number:19950-1AP, produced in rabbit,
1:1000) followed by incubation with an anti-rabbit-HRP secondary antibody (Santa Cruz Biotechnology,
Dallas, TX, USA, sc-2004, produced in goat, 1:3000). Chemiluminescence was detected by ECL
Substrate (Western Lightning Plus-ECL, PerkinElmer, Waltham, MA, USA). As a loading control,
actin was detected (after stripping of the membrane) by an anti-actin primary antibody (Santa Cruz
Biotechnology, sc-1616, produced in goat, 1:2000) and anti-goat-HRP secondary antibody (Santa Cruz
Biotechnology, sc-2354, produced in mouse, 1:3000).
2.12. Radioligand Binding Studies
Ligand competition assays with radiolabeled triptorelin were performed to evaluate the binding
affinity of K2 and 10 to GnRH-RI expressed on human pituitary and human prostate cancer cells as
reported earlier [34,40–42]. Tissue samples of human prostate cancer cells were obtained from a patient
at the time of initial surgical treatment and normal human pituitary tissue (anterior lobe) derived
by autopsy. All subjects gave their informed consent for inclusion before they participated in the
study. The collection and the use of these specimens for our studies were conducted in accordance
with the Declaration of Helsinki and approved by the local Institutional Ethics Committee (UD
REC/IEC 4831-2017). To study the binding affinity of the compounds, cell membrane homogenates
were prepared as previously described [34,40,41,43]. Apart from that, triptorelin was radioiodinated
using the chloramine-T method, followed by purification by RP-HPLC [34,40,41,44]. To determine
the binding affinities of the nonradio-labeled GnRH-III bioconjugates to GnRH-RI, the displacement
of [125I]-GnRH-I-[6D-Trp] was studied by an in vitro ligand competition assay [34,40–42]. Hence,
membrane homogenates which contained 50–160 mg protein were incubated in duplicate or
triplicate with 60–80,000 cpm [125I]-GnRH-I-[6D-Trp] and increasing concentration (1 pM–1 µM) of
nonradioactive bioconjugates as competitive binders in 150 mL binding buffer. To determine the
protein concentration by the method of Bradford, a Bio-Rad protein assay kit (Bio-Rad Laboratories,
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USA) was used. The LIGAND-PC computerized curve-fitting program of Munson and Rodbard was
used to determine the receptor binding characteristics and IC50 values [34,40–42].
2.13. Statistical Analysis
Due to the non-normal distribution (based on the performed Shapiro-Wilk normality tests),
Wilcoxon paired-sample tests were used to compare the effects of K2 and 10 on cell viability and on
cellular uptake [45]. A p-value < 0.05 was considered as significant. The statistical analyses were
performed using R version 3.4.1. [46].
3. Results
3.1. Synthesis and Characterization of Oxime Bond-Linked GnRH-III-Dau Bioconjugates
The GnRH-III-Dau conjugates were prepared by standard Fmoc-SPPS using orthogonal lysine
protecting groups (Scheme 1). Except for compound 13 (Supplementary Material Figure S1),
Fmoc-Ser(tBu)-OH or Fmoc-Lys(Dde)-OH was incorporated in position four and Fmoc-Lys(Mtt)-OH
in position eight. The Dde group was removed after peptide assembly followed by butyrylation
of the 4Lys side chain with butyric anhydride. Afterwards, the Mtt group was cleaved under
mild acidic conditions and Boc-Aoa-OH was coupled to the ε-amino group of 8Lys. All GnRH-III
peptides were cleaved from the resin with an appropriate TFA-scavenger mixture and purified by
reverse-phase HPLC. The conjugation of Dau to the aminooxyacetyl moiety was carried out in solution
by formation of an oxime bond [28]. All GnRH-III-Dau conjugates were purified again by preparative
HPLC. To prove the high purity (≥95%) of the final products and to ensure the absence of free Dau,
the bioconjugates were characterized by analytical HPLC using two different column types (C4 and
C18) and mass spectrometry (Table 1, Supplementary Material Figures S2–S17).
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Table 1. Chemical characteristics of GnRH-III-Dau conjugates.
Code [
8Lys(Dau=Aoa)]-GnRH-III
Compound
Purity [%] RP-HPLC Rt [min] a
ESI-MS MWcal/MWexp
[g/mol] b
K1 ≥97 21.37 1841.89/1841.66
1 [3D-Trp] ≥98 21.43 1841.89/1841.65
2 [3D-Tic] ≥98 21.22 1814.86/1814.65
3 [2∆His, 3D-Tic] ≥95 22.98 1677.72/1677.54
4 [3D-Tic, 7D-Trp] >97 21.58 1814.86/1814.62
5 [2∆His, 3D-Tic, 7D-Trp] ≥95 23.10 1677.72/1677.53
6 [6Asp(OMe)] ≥95 21.85 1855.91/1855.64
7 [10∆Gly-NHEt] ≥97 21.18 1812.88/1812.82
K2 [4Lys(Bu)] ≥99 22.41 1953.07/1952.79
8 [3D-Trp, 4Lys(Bu)] ≥98 22.83 1953.07/1952.65
9 [3D-Tic, 4Lys(Bu)] ≥97 22.57 1926.05/1925.73
10 [2∆His, 3D-Tic, 4Lys(Bu)] ≥96 24.27 1788.91/1788.64
11 [3D-Tic, 4Lys(Bu), 7D-Trp] ≥96 22.77 1926.05/1925.81
12 [2∆His, 3D-Tic, 4Lys(Bu), 7D-Trp] ≥98 24.27 1788.91/1788.68
13 [4Lys(Bu), 6Asp(OMe)] ≥98 22.92 1967.10/1966.68
14 [4Lys(Bu), 10∆Gly-NHEt] ≥97 23.17 1924.07/1923.72
a Column: Vydac 214TP5 C4 column (250 mm × 4.6 mm) with 5 µm silica (300 Å pore size); gradient: 0 min 0% B,
5 min 0% B, 40 min 90% B; eluents: 0.1% TFA in water (A) and 0.1% TFA in acetonitrile-water (80:20, v/v) (B); flow
rate: 1 mL/min; detection at 220 nm. b Bruker Daltonics Esquire 3000+ ion trap mass spectrometer.
3.2. In Vitro Cytostatic Effect of the Bioconjugates
Initially, GnRH-R expression was verified on HT-29, MCF-7 and MDA-MB-231 human cancer
cells by western blot analysis. All three cell lines display a band at approximately 38 kDa, which can
be considered as the full-length human GnRH-R (Supporting Information S18) [47]. Apart from that,
we detected additional bands with higher molecular weights (55–70 kDa), which is in accordance with
reported findings and can be assumed to be glycosylated forms of GnRH-Rs [48–50].
In order to investigate the influence of sequence modification on the in vitro cancer cell viability
of the novel GnRH-III-Dau bioconjugates, a resazurin based cell viability assay was performed.
The in vitro cytostatic effect was initially determined on estrogen-receptor α positive (ERα+) breast
adenocarcinoma cancer cells (MCF-7) and on colon carcinoma cells (HT-29). To ensure the comparability
to previous results, the well-studied GnRH-III bioconjugates GnRH-III-[8Lys(Dau=Aoa)] (K1) and
GnRH-III-[4Lys(Bu), 8Lys(Dau=Aoa)] (K2) were used as internal standards and positive controls [34,35].
All GnRH-III-Dau conjugates inhibited cell proliferation in a dose-dependent manner on MCF-7 as
well as on HT-29 human cancer cells (Table 2). We obtained IC50 values in the low micromolar range on
MCF-7 cells varying between 0.14 and 6.64 µM. In the case of HT-29 colon cancer cells, the determined
IC50 values were slightly higher and within a range of 3.31–19.10 µM. With exception of compound 10,
no significant difference of the cancer cell growth inhibitory effect of the novel bioconjugates and the
control conjugates (K1 and K2) could be detected. However, the replacement of 3Trp by 3D-Tic in
connection with the deletion of 2His led to an increased cytostatic effect of 10 on both of the analyzed
cell lines. The IC50 value of bioconjugate 10 was more than 15-times lower on ERα+ breast cancer MCF-7
cells and 5-times lower on colon cancer cells HT-29 compared to the control compound K2. Based on
these promising findings, the growth inhibitory effects of conjugate 10 and the related 2∆His-3D-Tic (3,
5 and 12) conjugates, as well as the 10∆Gly-NH-Et (7 and 14) containing compounds, were studied on
estrogen receptor negative (ERα-) MDA-MB-231 breast cancer cells. The corresponding IC50 values are
shown in Table 2. The GnRH-III-Dau conjugate 10 revealed also on this cell line the highest anticancer
activity with an IC50 value of 2.49 µM. The comparison of the dose-dependent growth inhibitory effect
of 10 and K2 on the three cancer cell lines is shown in Figure 1. Considering the results of all three cell
lines, only compound 10 which contains the N-terminal modification 2∆His-D-Tic-Lys(Bu), displayed
clearly a reduced cell viability, while the conjugates bearing other substitutions yielded IC50 values
which vary only slightly in comparison to the controls. The enhancement of the cytostatic effect might
be a result of an improved cellular uptake and/or release of the active metabolite in lysosomes. For a
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better understanding of our findings, we decided to perform further studies of candidate 10 in direct
comparison with our lead compound K2.
Table 2. In vitro cytostatic effects of GnRH-III-Dau conjugates on HT-29 human colon cancer, MCF-7
human and MDA-MB-231 human breast cancer cells.
Code [8Lys(Dau=Aoa)]-GnRH-III Compound HT-29 IC50 [µM] MCF-7 IC50 [µM] MDA-MB-231 IC50 [µM]
K1 13.89 ± 3.62 2.54 ± 0.67 8.22 ± 0.13
1 [3D-Trp] 15.25 ± 2.51 3.60 ± 0.28 n.d.
2 [3D-Tic] 8.75 ± 0.86 2.89 ± 0.62 n.d.
3 [2∆His, 3D-Tic] 10.32 ± 1.32 2.75 ± 0.17 9.35 ± 1.93
4 [3D-Tic, 7D-Trp] 15.34 ± 2.63 3.42 ± 0.39 n.d.
5 [2∆His, 3D-Tic, 7D-Trp] 10.70 ± 0.95 1.90 ± 0.58 7.88 ± 1.24
6 [6Asp(OMe)] 10.66 ± 1.76 4.81 ± 0.72 n.d.
7 [10∆Gly-NHEt] 14.18 ± 3.59 4.88 ± 0.01 14.33 ± 1.18
K2 [4Lys(Bu)] 15.93 ± 0.99 2.36 ± 0.07 9.00 ± 1.33
8 [3D-Trp, 4Lys(Bu)] 15.03 ± 2.51 6.64 ± 1.58 n.d.
9 [3D-Tic, 4Lys(Bu)] 12.73 ± 3.10 2.56 ± 0.51 n.d.
10 [2∆His, 3D-Tic, 4Lys(Bu)] 3.31 ± 0.90 0.14 ± 0.01 2.49 ± 0.53
11 [3D-Tic, 4Lys(Bu), 7D-Trp,] 16.83 ± 0.66 2.57 ± 0.47 n.d.
12 [2∆His, 3D-Tic, 4Lys(Bu), 7D-Trp] 16.55 ± 0.30 2.81 ± 0.04 8.18 ± 0.18
13 [4Lys(Bu), 6Asp(OMe)] 18.00 ± 0.13 3.44 ± 0.51 n.d.
14 [4Lys(Bu), 10∆Gly-NHEt] 17.84 ± 0.08 2.23 ± 0.40 12.41 ± 2.30
n.d.—not determined, all values represent mean ± SE.
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Figure 1. Cytostatic effect of the GnRH-III conjugate K2 (●) and 10 (▲) on MCF-7 (left), HT-29 
(middle) and MDA-MB-231 (right) human cancer cells after 72 h (24 h treatment and an additional 48 
h incubation). Curves obtained by non-linear regression (sigmoidal dose response, error bars 
represent the standard deviation of four parallels, the measurements were repeated twice). 
3.3. Stability in Human Plasma 
The stability of peptide-drug conjugates in human blood plasma is of great importance for the 
therapeutic application. Therefore, the stability of our two lead compounds K2 and 10 was 
determined in 90% human plasma and detected by LC-MS. Both GnRH-III-Dau conjugates were 
stable in human plasma for at least 24 h at 37 °C, which is of great importance for upcoming in vivo 
studies (Supplementary Figure S18). 
3.4. Degradation of GnRH-III Bioconjugates in Rat Liver Lysosomal Homogenate 
To enable the selective delivery of the drug to cancer cells, not only the stability under 
physiological conditions is of high relevance but also the release of the drug or active drug 
metabolites at the tumor tissue. Therefore, we determined the release of the smallest Dau-containing 
metabolite in presence of rat liver lysosomal homogenate. The degradation of the conjugates K2 and 
Figure 1. Cytostatic effect of the GnRH-III conjugate K2 ( ) and 10 (N) on F-7 (left), T-29
( iddle) and D - B-231 (right) hu an cancer cells after 72 h (24 h treatment and an additional 48 h
incubation). Curves obtained by non-linear regression (sigmoidal dose response, error bars represent
the standard deviation of four parallels, the measurements were repeated twice).
3.3. Stability in Human Plasma
The stability of peptide-drug conjugates in human blood plasma is of great importance for
the therapeutic application. Therefore, the stability of our two lead compounds K2 and 10 was
determined in 90% human plasma and detected by LC-MS. Both GnRH-III-Dau conjugates were stable
in human plasma for at least 24 h at 37 ◦C, which is of great importance for upcoming in vivo studies
(Supplementary Figure S18).
3.4. Degradation of GnRH-III Bioconjugates in Rat Liver Lysosomal Homogenate
To enable the selective delivery of the drug to cancer cells, not only the stability under
physiological conditions is of high relevance but also the release of the drug or active drug metabolites
at the tumor tissue. Therefore, we determined the release of the smallest Dau-containing metabolite
in presence of rat liver lysosomal homogenate. The degradation of the conjugates K2 and 10 and
thereby the formation of the smallest Dau-containing metabolite was followed by LC-MS at different
time points. Due to the high stability of the oxime bond, the free drug could not be detected. Both
conjugates were degraded resulting in various peptide fragments (Figure 2 and Supporting Information
Table S1). In general, K2 displayed a higher lability in the presence of the lysosomal enzymes than
10, especially the N-terminal region of K2 was less stable. Nevertheless, the presence of the smallest
Dau metabolite H-Lys(Dau=Aoa)-OH could already be detected after 1 h of incubation for both
GnRH-III-Dau derivatives, which is of high relevance for the biological activity of the conjugate.
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3.5. Cellular Uptake Determination by Flow Cytometry
To compare the cellular uptake of K2 and 10, MCF-7 and HT-29 cells were treated with different
concentrations of compounds and after 6 h incubation, flow cytometry studies were carried out.
Hereby, only living cells have been considered revealing that compound 10 was taken up more
effectively than K2 in both cancer cell lines (Figure 3). In the case of MCF-7 cells, the uptake was at
the lowest compound concentration (3.125 µM) already 4 times higher for 10 (14.55%) than for K2
(3.5%). At 6.25 µM concentration, 54.2% (10) and 19.35% (K2) of living cells were Dau positive, while at
12.5 µM compound concentration, 94% (10) and 63.8% (K2) uptake could be detected. At the two
highest concentrations (25 and 50 µM), the cellular uptake on MCF-7 cells was between 96.45 and
100% for both conjugates. On HT-29 colon cancer cells, bioconjugate 10 (3.125 µM) was taken up by
9.15% of the cells whereby the uptake of K2 was 3.25%. This tendency remains similar for the other
concentrations, while at the highest concentration (50 µM), a cellular uptake of 99.3% was detected for
compound 10 and 92.5% for K2. Considering these results, we assume that the improved cytostatic
effect is mainly related to the improved cellular uptake of compound 10.Pharmaceutics 2018, 10, x FOR PEER REVIEW  11 of 19 
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Figure 3. Cellular uptake of the GnRH-III conjugates K2 and 10 on MCF-7 (left) and HT-29 (right)
cancer cells after 6 h treatment determined by flow cytometry. The cellular uptake of 10 was
significantly higher than the uptake of conjugate K2 for both cells (paired Wilcoxon test, p = 0.004 and
p = 0.005, respectively).
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3.6. Cellular Uptake Determination by Confocal Microscopy Imaging
In order to visualize the cellular uptake and the localization of compound 10 in MCF-7 breast
cancer cells, confocal fluorescence microscopy studies were performed. The cells were incubated
with the conjugate (40 µM) for different time intervals from five seconds up to one hour, followed
by fixation and preparation for imaging. DAPI-staining was performed to verify the localization
of Dau and Dau-containing metabolites in the nuclei. After 5 min incubation, the Dau signal was
detected mainly in the nuclei, whereby the obtained images within the first minute display the Dau
signal predominantly in the cytosol and in small vesicles (Figure 4). These results indicate that the
drug-conjugate could be efficiently taken up by the cancer cells and reached its site of action already
within 5 min.
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3.7. Radioligand Binding Studies
To ensure that the cellular uptake is related to the receptor-mediated pathway, we determined
the binding affinities of bioconjugate 10 and our lead compound K2 to GnRH-receptors by ligand
competition assay. Increasing concentrations of the conjugates were used to displace radiolabeled
triptorelin from GnRH-receptors expressed on human pituitaries and human prostate cancer tissues.
The binding affinity of bioconjugate 10 was compared with that of our lead compound K2. Both
conjugates displaced [125I]-triptorelin with high potency and their IC50 values were in the low
nanomolar range. Both conjugates revealed a similar binding affinity for human pituitary tissues (10:
3.53 ± 0.96 nM and K2: 3.59 ± 2.17 nM) and human prostate cancer tissues (10: 2.79 ± 1.24 nM and
K2: 3.43 ± 2.01 nM; Figure 5). These low nanomolar IC50 values of K2 and 10 demonstrated that both
conjugates have a high binding affinity to the GnRH-receptors and that the receptor binding is not
influenced by the N-terminal amino acid substitution of compound 10.
Pharmaceutics 2018, 10, 223 12 of 19
Pharmaceutics 2018, 10, x FOR PEER REVIEW  12 of 19 
 
3.7. Radioligand Binding Studies 
To ensure that the cellular uptake is related to the receptor-mediated pathway, we determined 
the binding affinities of bioconjugate 10 and our lead compound K2 to GnRH-receptors by ligand 
competition assay. Increasing concentrations of the conjugates were used to displace radiolabeled 
triptorelin from GnRH-receptors expressed on human pituitaries and human prostate cancer tissues. 
The binding affinity of bioconjugate 10 was compared with that of our lead compound K2. Both 
conjugates displaced [125I]-triptorelin with high potency and their IC50 values were in the low 
nanomolar range. Both conjugates revealed a similar binding affinity for human pituitary tissues (10: 
3.53 ± 0.96 nM and K2: 3.59 ± 2.17 nM) and human prostate cancer tissues (10: 2.79 ± 1.24 nM and K2: 
3.43 ± 2.01 nM; Figure 5). These low nanomolar IC50 values of K2 and 10 demonstrated that both 
conjugates have a high binding affinity to the GnRH-receptors and that the receptor binding is not 
influenced by the N-terminal amino acid substitution of compound 10. 
 
Figure 5. Representative displacement of [125I]-GnRH-I-[6D-Trp] binding to membrane fractions of 
human prostate cancer specimens by increasing concentrations of GnRH-III conjugates 10 (●) and K2 
(▼). Other unrelated peptides, like somatostatin, human growth hormone and epidermal growth 
factor (♦) did not displace the radioligand. Each point represents the mean of duplicate or triplicate 
determinations. 
4. Discussion 
Cancer is one of the most serious diseases worldwide and according to the WHO this 
malignancy was the second leading cause of death with 8.8 million deaths in 2015 [51]. Due to this, 
the development of efficient diagnostic and therapeutic tools is of high relevance. One promising 
approach for the treatment of cancer is targeted tumor therapy, which is based on the fact that 
receptors for many regulatory ligands are highly expressed in many tumor cells. Due to this, hormone 
peptides like GnRH and its derivatives are promising homing devices for the selective delivery of 
antitumor drugs to cancer cells. The use of GnRH derivatives for targeted tumor therapy offers 
valuable benefits since they possess an antiproliferative activity, which provides an additional 
inhibitory effect on tumor growth [52]. Furthermore, it has been reported that GnRH-Rs are not only 
expressed in reproductive system related tumors but also in unrelated cancer types, which extend 
the potential of their use as targets in cancer therapy [53]. 
Apart from human GnRH-I, many native GnRH isoforms have been isolated from different 
species showing that the N- and C-terminal regions are highly conserved and essential for receptor 
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Figure 5. Representative displacement of [125I]-GnRH-I-[6D-Trp] binding to membrane fractions
of human prostate cancer specimens by increasing concentrations of GnRH-III conjugates 10 ( )
and K2 (H). Other unrelated peptides, like somatostatin, human growth hormone and epidermal
growth factor () did not displace the radioligand. Each point represents the mean of duplicate or
triplicate determinations.
4. Discussion
Cancer is one of the most serious diseases worldwide and according to the WHO this malignancy
was the second leading cause of death w th 8.8 million deaths in 2015 [51]. Due to this, the development
of efficient diagnostic and ther peuti tools is of high relevance. One promising approach for t e
treatm nt f cancer is targ ted tumor therapy, which is based on the fact that re ptors fo any
regulatory ligands are highly expressed in many tumor cells. Due to this, hormone p ptides like GnRH
and its derivatives ar promisin homing devices for th selective delivery of antitumor drugs to
cancer c lls. The use of GnRH derivatives for targeted tumor therapy offers valuable benefits since
they possess an an iprolif rative activity, which provi s an addition l inhibitory effect on tumor
growth [52]. Furthermore, it has been reported that GnRH-Rs are not only expresse in repro uctive
system relat d tumors but als in unrelated cancer types, which extend the pote tial of their use as
targets in cancer therapy [53].
Apart from human GnRH-I, many ative GnRH isoforms have been isolated from different
species showing that the N- and C-terminal regions are highly conserved a d essential f r receptor
binding and activi y [54,55]. These studies hav shown that the activ conformation of mammalian
GnRH exhibits a β- urn structur formed by residues 5–8 wher by th N- and C-termini f ce e ch
other [54,55]. Howeve , NMR studies comparing the human GnRH-I and the sea lamprey nalog
GnRH-III pointed out that their conformations e substantially different. While the results of GnRH-I
confirm a defined U-shape structure, GnRH-III seems to be less bent and according o th NMR spectra,
an ordered extended backbon conformation can be propo ed [38]. Moreover, it could be demonstrated
that amino acid substitutions within the GnRH-III sequence can lead to an improved antiproliferative
activity even if the replaced residues are assumed to be crucial for the biological activity [38].
The aim of the present study was to develop novel GnRH-III-Dau conjugates with an improved
antitumor activity by incorporating various unnatural amino acids within the peptide sequence.
Hereby, we paid special attention to the effect of amino acid exchange in position seven by D-Trp and
the replacement of 3Trp by D-Trp as well as D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (D-Tic)
and in combination with 2His deletion. Moreover, we investigated the influence of 6Asp side chain
methylation and of modifying the C-terminus to 10∆Gly-NHEt. Based on our previous studies, which
pointed out that an exchange of 4Ser by 4Lys(Bu) results in an enhanced in vitro and in vivo anticancer
activity, we decided to investigate two sets of GnRH-III-Dau conjugates containing either the natural
serine in position four or Lys(Bu).
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In the present work, we report the synthesis and biological evaluation of 14 novel oxime
linked GnRH-III-Dau conjugates. After synthesis and purification, the final conjugates have been
analyzed for their cytostatic effect on reproductive system related (MCF-7) and unrelated (HT-29)
GnRH-R expressing cancer cells. Due to the fact that immortal cell lines can differ in their genotypic
and phenotypic characteristics depending on the passage and state of confluence, we used our
well-established GnRH-III-Dau derivatives K1 and K2 for a better comparison and as an internal
standard [34,35]. All new analogs showed a significant growth inhibitory effect on both human cancer
cell lines with IC50 values in the low micromolar range, which vary only slightly from that of the
control peptides. Besides that, the conjugate GnRH-III-[2∆His, 3D-Tic, 4Lys(Bu), 8Lys(Dau=Aoa)]
(10) revealed an improved inhibitory effect on the growth of both cancer cell lines, whereby the
cytostatic effect on MCF-7 breast cancer cells was increased by more than one order of magnitude
in comparison to K2. In contrast, the C-terminal modification 10∆Gly-NHEt (7, 14) did not result in
a significant change of the cell viability in comparison with the control peptides (K1, K2) on both
cell lines. These results are in agreement with earlier studies of drug-free GnRH-III derivatives [56],
while in case of GnRH-I derivatives, the replacement of Gly-NH2 with ethyl amide provides the more
potent GnRH-I agonist fertirelin [57,58]. Moreover, by combining the modification 9Pro-NHEt with
6Gly replacement by D-amino acids, superagonists like buserelin or leuprolide are produced, which
possess a much higher activity than the native GnRH-I or fertirelin [12,58]. It could be shown that the
increased activity is mainly related to the 6Gly substitution since D-amino acids in position six enhance
the β-turn conformation of GnRH-I agonists [55]. On the contrary, the incorporation of various 6D-Aaa
did not result in an improved biological activity of GnRH-III-Dau conjugates [42]. Apart from that,
it could be shown that the negative charge of the 6Asp side chain is not mandatory for the biological
activity of GnRH-III, beyond that the methylation of the aspartate residue results in an enhanced
cytostatic effect [38,59]. In contrast, the methylation of GnRH-III-Dau conjugates (6, 13) could not
cause a significant change of the cytostatic effect; although our results confirm that the acidic character
of 6Asp is not essential for the activity of the conjugates.
According to Sealfon, the residues 2His and 3Trp might play an important role in receptor
activation and biological activity of GnRH-I derivatives [54]. On the other hand, it has been reported
that an exchange of 3Trp with D-Trp and D-Tic reduces the receptor binding affinity of GnRH-I analogs
but provides an increased antiproliferative activity on MCF-7 cells [60]. However, our results of the
GnRH-III-Dau conjugates, which have been modified in the 2His-3Trp and/or 7Trp positions revealed
no substantial deterioration of the antitumor activities, which is in line with previous studies [38].
Initially, we analyzed the influence of replacing 3Trp by D-Trp and D-Tic. The results displayed a
slightly improved biological activity of the D-Tic conjugates 2 and 9 on HT-29 cells. In the next step,
we studied the influence of 2His deletion and/or 7D-Trp substitution in combination with 3D-Tic.
On all three cell lines, the strongest positive impact on the biological activity could be observed for
conjugate 10 with the N-terminal modifications 2∆His-3D-Tic-4Lys(Bu). In order to interpret these
outcomes, we decided to perform further studies of candidate 10 in direct comparison with our lead
compound K2.
To ensure the stability of the conjugates under physiological conditions, we analyzed their
durability in human blood plasma revealing that both conjugates are stable for at least 24 h, which is in
accordance with our previous results of related GnRH-III-Dau derivatives [35,61]. Next to compound
stability in circulation, the release of the drug within cancer cells is of high relevance. Due to the high
chemical and enzymatic stability of the oxime bond, we could not detect the release of the free Dau by
lysosomal enzymes, which is in agreement with prior results [34,35,42]. Nevertheless, DNA-binding
studies could prove that also small Dau-containing metabolites can intercalate in DNA and thereby
inhibit topoisomerase II activity, which leads to a substantial reduction of cell proliferation [29].
The degradation profile of 10 and K2 in presence of lysosomal enzymes shows that the N-terminal
part Glp-D-Tic-Lys(Bu)-His-Asp of 10 is more resistant to lysosomal enzymes. In accordance with our
recent studies, already after 5 min of incubation, we could detect the fragments <EHWK(Bu)-OH and
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H-HDWK(Dau=Aoa))PG-NH2 for K2 giving a clear evidence of the endopeptidase activity [42]. In spite
of the enhanced stability of 10, the smallest Dau-containing metabolite H-Lys(Dau=Aoa)-OH could be
detected within the first hour for both conjugates. Due to the detected fragments, we assume that the
active metabolite H-Lys(Dau=Aoa)-OH is rapidly released by lysosomal enzymes with carboxymono-
and dipeptidase activity resulting in an efficient biological activity of both conjugates.
Since anthracyclines like Dau are highly fluorescent molecules, the cellular uptake of
GnRH-III-Dau conjugates can be studied by fluorescence-activated cell sorting (FACS) and/or confocal
laser scanning microscopy (CLSM) without changing the inherent properties of the compounds [62].
Thus, the uptake rate of K2 and 10 on HT-29 and MCF-7 human cancer cells was investigated by
flow cytometry. The obtained results display an increased cellular uptake for the new conjugate 10
on both cell lines. Especially, the uptake rates at low compound concentrations are considerably
improved in comparison to K2 indicating that the enhanced biological activity of 10 is mainly
related to the improved cellular uptake. Besides the quantitative uptake studies by flow cytometry,
we examined the subcellular disposition of compound 10 in a time-dependent manner by CLSM. In the
first minute, the Dau signal was mainly detected in small cytosolic vesicles, while after five minutes the
Dau-fluorescence could be predominantly identified in the nuclei. Considering that comparable study
of K2 revealed the necessity of 10 min incubation to observe the presence of Dau in nuclei, it can be
assumed that the delivery of the drug to its site of action is accelerated by using bioconjugate 10 [42].
According to Zompra, the incorporation of 3D-Tic in GnRH-I derivatives can lead to a substantially
reduced GnRH-receptor affinity, while the inhibitory effect on cell proliferation is increased [60].
To validate that the anticancer effect of the novel compound is still related to GnRH-receptor
binding, we determined the receptor affinity of 10 and K2 by displacement studies with radiolabeled
[125I]-triptorelin. Based on our results both compounds bind to GnRH-receptors expressed on human
pituitaries and prostate cancer tissues with high binding affinities. Moreover, the results obtained for
K2 are nicely comparable to our recent studies [42].
The low nanomolar IC50 values of both GnRH-III conjugates demonstrated that the binding of
GnRH-I agonist triptorelin was efficiently inhibited in a competitive manner by using increasing
concentrations of 1 pM to 1 µM. By taking into account that peptides unrelated to GnRH like
somatostatin-14 or bombesin were not able to displace triptorelin by applying concentrations up
to 1 µM, it can be assumed that the receptor-mediated uptake was not affected by the performed amino
acid substitutions [40,41].
Considering these findings, bioconjugate 10 represents a highly promising candidate for in vivo
antitumor activity studies in tumor-bearing mice. But since the tumor growth of MCF-7 cells for
breast cancer xenograft depends strongly on exogenous 17β-estradiol (E2) support we analyzed the
in vitro cytostatic effect of 10 also on GnRH-R positive, but ERα negative MDA-MB-231 breast cancer
cells [63,64]. For a better interpretation, we include all 2∆His-3D-Tic containing conjugates (3, 5, 10
and 11) and the C-terminally modified GnRH-III-Dau (7, 14) conjugates in this study. The obtained
results revealed a similar tendency of the tumor growth inhibitory effect as we detected for MCF-7
and HT-29 cells, whereby GnRH-conjugate 10 displays a significant increase in cell growth inhibition
compared to K2. Moreover, it has been reported that MDA-MB-231 breast cancer cells are not only
ERα- but also progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER-2)
negative [63,65,66]. Due to the fact that these triple negative (ERα-/PgR-/Her-2) cancer cells are
considered to be very aggressive and since some commonly used chemotherapeutics like Herceptin
(HER-2 targeting) lack activity on these kinds of cells, alternative approaches are necessary to affect
such tumor types. Our findings support the assumption that GnRH-receptor might be a potential target
to overcome these limitations since GnRH-Rs are expressed in more than 50% of human breast cancer.
In conclusion, all 14 novel GnRH-III-Dau conjugates demonstrate an efficient cancer cell growth
inhibition in vitro. Especially the conjugate GnRH-III-[2∆His,3D-Tic,4Lys(Bu),8Lys(Dau=Aoa)] (10)
displays an increased cytostatic effect on all analyzed cancer cell lines in comparison to the lead
compound K2. The detailed biochemical characterization of bioconjugate 10 indicates that this
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N-terminal modification leads to an improved cellular uptake of the conjugate which is accompanied
by an accelerated delivery of the drug to its site of action. Receptor binding studies demonstrated
the high binding affinity of our compound to GnRH-receptors expressed on human cancer tissue.
Furthermore, we could ensure that the release of the active drug metabolite in lysosomes is not retarded
by the D-amino acid substitutions, while the compound provides a high stability in human blood
plasma which is of great importance for upcoming tumor growth inhibitory studies in vivo.
All findings of the present study demonstrate the great value of our new lead compound and
indicate its high potential as a promising drug delivery system in targeted tumor therapy. In vivo
studies on tumor-bearing mice are planned for the near future to further confirm its application as an
efficient agent for selective cancer therapy.
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